Fundamental analysis · SEC EDGAR · as of 24/04/2026

Fundamental analysis of Medtronic Plc

MDT · NYSE · Healthcare

Fundamental quality

REASONABLE

65

out of 100

Medtronic Plc earns a fundamental-quality score of 65 out of 100, profiling it as a company of reasonable quality. Its score rests mainly on its financial strength (net debt 2.76× EBITDA). Its weakest area is its growth (revenue +3.9%/yr). Whether it's cheap or expensive depends on the current price, which you can compute in the tool.

What the company does

Medtronic is one of the world's largest medical-device makers: pacemakers, insulin pumps, neurostimulators and surgical robotics. Its scale and presence in dozens of countries give it the steady demand typical of healthcare.

What will shape its future

  • Its ability to speed up growth in newer areas (diabetes, surgical robotics) against a mature core.
  • An aging population and surgery volumes, which underpin its baseline demand.
  • Cost efficiency and niche-by-niche competition with more agile, specialized rivals.

Breakdown by area

I.Growth
46

EPS growth: 7% · Revenue growth: 3.9%

II.Profitability
66

Net margin: 13.2% · ROE: 9.7% · ROIC: 6.8%

III.Financial health
71

Net debt/EBITDA: 2.76x · FCF: 14.9%

Source: SEC EDGAR · as of 24/04/2026

The score includes +4 for dividend strength: 50 consecutive years of increases. Keeping that streak demands growing cash generation and balance-sheet discipline.

The score combines growth, profitability and financial strength. Here its financial strength weighs in its favor, while its growth drags it down the most.

Versus its sector

Percentile against the other 57 Healthcare companies in our coverage: how far it beats them on each metric (100 = best in sector).

Net marginbeats 57%
ROEbeats 31%
Growthbeats 19%
Cash generationbeats 48%
Less debtbeats 34%

Computed from the daily dataset scores. A high percentile places the company among the best in its sector on that metric; it is not a buy recommendation.

Key concepts

What do these metrics mean? Fundamental analysis · What is the P/E · What is EPS · What is ROE · Net & gross margin · Free cash flow

Medtronic Plc strengths

  • Strong free-cash-flow generation (FCF margin of 14.9%): profit turns into real cash.
  • Solid net margin (13.2%): the business is clearly profitable.
  • Positive free cash flow year after year, a self-funding business.

Medtronic Plc risks and weaknesses

  • No clear weaknesses in the recent fundamentals, though the system doesn't assess qualitative factors (competition, regulation, management).

Medtronic Plc historical evolution

YearRevenueNet incomeFree cash flowNet debt
202130,1173,6064,88522,796
202231,6865,0395,97820,400
202331,2273,7584,58022,821
202432,3643,6765,20023,740
202533,5374,6625,18526,298
202636,3644,8015,42626,012

Between 2021 and 2026, revenue went from $30,117M to $36,364M (+21%) and net income went from $3,606M to $4,801M (+33%).

Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.

Dividend

$2.84

per share, yearly

75.8% of earnings

Payout

50 straight years raising it

Growth

The dividend yield depends on today's price. Compute it in the analyzer → · See all dividend-paying stocks →

Advertising

Want to invest in Medtronic Plc?

Open your account in minutes with regulated brokers and buy U.S. and European stocks from small amounts. No paperwork.

Interactive BrokersGlobal markets

The serious investor's standard

Open free account →
WebullCommission-free

Popular in the U.S.

Open free account →

Investing carries risk of loss.

Is Medtronic Plc cheap or expensive?

That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).

Compute the valuation →

Frequently asked questions

Is Medtronic Plc a good company to invest in?

In terms of business quality, Medtronic Plc scores 65 out of 100 in our analysis, placing it as a company of reasonable quality. That said, this isn't a recommendation: whether it's a good investment also depends on its current price and your goals.

Is Medtronic Plc a profitable company?

Yes. Medtronic Plc shows a net margin of 13.2% and an ROE of 9.7%, a sign of a profitable business.

Does Medtronic Plc have a lot of debt?

A moderate level: its net debt is 2.76 times its EBITDA.

Is Medtronic Plc growing?

Its revenue has grown 3.9% annualized in recent years and its earnings per share 7%.

Does Medtronic Plc generate cash?

Yes. It converts about 14.9% of its revenue into free cash flow, and has done so positively year after year.

The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.

Was this page helpful?